<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04506411</url>
  </required_header>
  <id_info>
    <org_study_id>0120-118/2020/9</org_study_id>
    <nct_id>NCT04506411</nct_id>
  </id_info>
  <brief_title>Turmeric Efficacy for Mobility and Joint Function</brief_title>
  <acronym>T-MOTION</acronym>
  <official_title>Placebo Controlled Randomized Clinical Trial to Evaluate Efficacy of Turmipure Gold® to Improve Joint Function in Subjects With Distinct Kellgren-Lawrence Knee Radiographic Scores</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naturex SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Artialis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vizera d.o.o.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Naturex SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to test the capacity of a 12-weeks Turmipure GOLD®&#xD;
      supplementation to reduce joint discomfort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this clinical study is to determine whether oral administration of Turmipure GOLD®&#xD;
      can contribute to the improvement of mobility and joint function in adult population with&#xD;
      knee discomfort and with distinct Kellgren-Lawrence (K&amp;L) knee radiographic scores.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Actual">March 3, 2023</completion_date>
  <primary_completion_date type="Actual">March 3, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in WOMAC™ Pain</measure>
    <time_frame>12-weeks</time_frame>
    <description>Knee joint pain discomfort assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Pain subscore (WOMAC A) ranges from 0 to 100 mm (averaging five VAS 0-100 mm) with higher scores indicating more pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC™ Stiffness</measure>
    <time_frame>12-weeks</time_frame>
    <description>Knee joint stiffness assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Stiffness subscore (WOMAC B) ranges from 0 to 100 mm (averaging two VAS 0-100 mm) with higher scores indicating more stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC™ Physical function</measure>
    <time_frame>12-weeks</time_frame>
    <description>Knee joint physical function assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Physical function subscore (WOMAC C) ranges from 0 to 100 mm (averaging seventeen VAS 0-100 mm) with higher scores indicating more stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC™ Global Index</measure>
    <time_frame>12-weeks</time_frame>
    <description>Knee joint global discomfort assessed through the sum of WOMAC A (pain), WOMAC B (stiffness) and WOMAC C (physical function) subscores. The WOMAC Global Index score ranges from 0 to 2400 mm (summing up twenty-four VAS 0-100 mm), with higher scores indicating higher disease burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity at rest</measure>
    <time_frame>12-weeks</time_frame>
    <description>The pain intensity at rest is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity while walking</measure>
    <time_frame>12-weeks</time_frame>
    <description>The pain intensity while walking is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Patient Global Assessment&quot; (PGA)</measure>
    <time_frame>12-weeks</time_frame>
    <description>The &quot;Patient Global Assessment&quot; (PGA) is the global assessment on joint discomfort and is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI criteria</measure>
    <time_frame>12-weeks</time_frame>
    <description>Evaluation of the response to supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30s Chair Stand Physical Performance</measure>
    <time_frame>12-weeks</time_frame>
    <description>Evaluation of the maximum number of chair stand repetitions possible in a 30 second period. Scoring results in a wide range of skill levels from 0, for those who cannot complete a single repetition and values greater than 20 for the well prepared individuals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>40m Fast-paced Walked Physical Performance</measure>
    <time_frame>12-weeks</time_frame>
    <description>A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) evaluating the ability to walk quickly over short distances. Time of one test trial is recorded and expressed as speed m/s by dividing distance (40m) by time (s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stair Climb Physical Performance</measure>
    <time_frame>12-weeks</time_frame>
    <description>Evaluates the time (in seconds) it takes to ascend and descend a flight of stairs. Timing begins on the signal to start and terminates when the participant returns with both feet to the ground level and the total time to ascend and descend steps for 1 test trial is recorded to nearest 100th of a second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time up &amp; Go Physical Performance</measure>
    <time_frame>12-weeks</time_frame>
    <description>Evaluates the time (seconds) taken to rise from a chair, walk 3 m (9 ft 10 inches), turn, walk back to the chair, then sit down. Timing starts on the signal to start and terminates once the participant sits back down fully with their back resting on the back of the chair. Two trials are performed and the faster of the 2 trials is recorded to nearest 10th of a second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life evaluation</measure>
    <time_frame>12-weeks</time_frame>
    <description>Evaluation of Quality of life through SF-36 (RAND version), which is a set of generic, coherent, and easily administered quality-of-life measures. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability and the higher the score the less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGIC)</measure>
    <time_frame>12-weeks</time_frame>
    <description>Physician assessment of joint swelling and range of motion (ROM) for knee extension/flexion, indicating the perceived change over the treatment period. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of use of rescue medicine</measure>
    <time_frame>12-weeks</time_frame>
    <description>Evaluation of associated treatments needed to manage joint complains</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Knee Discomfort</condition>
  <condition>Joint Pain</condition>
  <arm_group>
    <arm_group_label>TPG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Turmipure GOLD®</intervention_name>
    <description>TPG: Turmipure GOLD® capsules - 4 capsules once daily- as prescribed</description>
    <arm_group_label>TPG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Turmeric rhizome PE 95% curcuminoids</intervention_name>
    <description>STE: Turmeric rhizome PE 95% curcuminoids - 4 capsules once daily- as prescribed</description>
    <arm_group_label>STE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: Maltodextrin - 4 capsules once daily- as prescribed</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consent to the study and to comply with study product&#xD;
&#xD;
          -  Who have a BMI between 18 and 32 kg/m²&#xD;
&#xD;
          -  Who has mild to moderate knee pain for at least 3 months before enrollment (VAS&#xD;
             between 40 to 70 on 100mm scale after respecting a washout period depending on the&#xD;
             half-life of the excluded medications)&#xD;
&#xD;
          -  Who has radiographic evidence of Kellgren-Lawrence score 0, 1, 2 and 3 in the&#xD;
             tibio-femoral compartment of the target knee&#xD;
&#xD;
          -  Who is able to perform the physical performance-based tests and understands all&#xD;
             questions from the WOMAC questionnaire&#xD;
&#xD;
          -  Who is willing to refrain from taking any pain reliever (OTC or prescription) and&#xD;
             other pharmacological, nutritional agent (e.g. glucosamine), device or therapy (e.g.&#xD;
             acupuncture) which may influence the study outcome during the entire trial (other than&#xD;
             determined authorized rescue medication)&#xD;
&#xD;
          -  Who is willing to not change dietary habits, level of physical activity (including any&#xD;
             heavy physical work with high loading of the knee joints) and body weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any clinically significant levels of the safety parameters at screening&#xD;
&#xD;
          -  Pregnant or lactating females, or wishing to become pregnant during the study&#xD;
&#xD;
          -  Subject with joint pain related to some predisposing conditions that have adversely&#xD;
             altered the joint tissues often due to a specific cause&#xD;
&#xD;
          -  Subject with Kellgren-Lawrence grade 4 in the tibio-femoral compartment of the target&#xD;
             knee&#xD;
&#xD;
          -  Who has clinically apparent tense effusion of the target knee or other joint&#xD;
&#xD;
          -  Who has/had viscosupplementation in any joint including the target knee or other joint&#xD;
             within 6 months prior to screening&#xD;
&#xD;
          -  Who has concomitant inflammatory disease or other condition that affects the joints&#xD;
             deemed exclusionary by the Principal Investigator (e.g. rheumatoid arthritis,&#xD;
             metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis and active&#xD;
             infection, etc…)&#xD;
&#xD;
          -  Who has symptomatic osteoarthritis of the contralateral knee that is not responsive to&#xD;
             paracetamol and requires other therapy&#xD;
&#xD;
          -  Who is taking any treatment/supplementation which may interfere with study conduct and&#xD;
             interpretation of study results (4-weeks washout, e.g. glucosamine, chondroitin,&#xD;
             corticosteroids) except calcium and vitamin D supplements&#xD;
&#xD;
          -  Who is under any medical condition deemed exclusionary by the Principal Investigator&#xD;
&#xD;
          -  Subject has a history of drug and / or alcohol abuse at the time of enrollment&#xD;
&#xD;
          -  Change of dietary habit within the preceding month&#xD;
&#xD;
          -  Subject with known organic disease, including an inflammatory bowel disease, a benign&#xD;
             or malign tumor of intestine or colon and significant systemic disease&#xD;
&#xD;
          -  Subject currently involved in any other clinical trial or having participated in a&#xD;
             trial within the preceding 90 days&#xD;
&#xD;
          -  Subject with known allergy to components of the test product&#xD;
&#xD;
          -  Subject has any concurrent medical or psychiatric condition that, in the opinion of&#xD;
             the Investigator, would compromise his/her ability to comply with the study&#xD;
             requirements&#xD;
&#xD;
          -  History of cancer within the last 5 years, except basal cell carcinoma, non-squamous&#xD;
             skin carcinoma, prostate cancer or carcinoma in situ with no significant progression&#xD;
             over the past 2 years&#xD;
&#xD;
          -  Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune&#xD;
             disorder, or metabolic/endocrine disorders or other disease that would preclude&#xD;
             supplement ingestion and/or assessment of safety and the study objectives&#xD;
&#xD;
          -  Current illnesses which could interfere with the study (e.g. prolonged severe&#xD;
             diarrhea, regurgitation/severe, difficulty swallowing)&#xD;
&#xD;
          -  Who is taking any anticoagulant or heparin treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matija Tomšič, Prof., MD</last_name>
    <role>Study Chair</role>
    <affiliation>Univerzitetni klinični center Ljubljana, Klinični oddelek za revmatologijo, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samo K Fokter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univerzitetni klinični center Maribor, Oddelek za ortopedijo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Poliklinika Aviva</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika Idassa</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortopedska bolnišnica Valdoltra</name>
      <address>
        <city>Ankaran</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Splošna bolnišnica Jesenice, Oddelek za ortopedijo</name>
      <address>
        <city>Jesenice</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bisturmed, d.o.o., Ortopedija in fizioterapija</name>
      <address>
        <city>Koper</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika Nobilis, d.o.o., enota LJ, Ortopedska ambulanta</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinsko termalni center Fontana, d.o.o., Ortopedska ambulanta</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitetni klinični center Maribor, Oddelek za ortopedijo</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>May 2, 2023</last_update_submitted>
  <last_update_submitted_qc>May 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mobility</keyword>
  <keyword>Joint function</keyword>
  <keyword>Turmeric</keyword>
  <keyword>Curcuminoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To revisit after investigation period</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04506411
org study id: 0120-118/2020/9
nct id: NCT04506411
lead sponsor: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The objective of the study is to test the capacity of a 12-weeks Turmipure GOLD®
      supplementation to reduce joint discomfort.
The aim of this clinical study is to determine whether oral administration of Turmipure GOLD®
      can contribute to the improvement of mobility and joint function in adult population with
      knee discomfort and with distinct Kellgren-Lawrence (K&L) knee radiographic scores.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Change in WOMAC™ Pain
time frame: 12-weeks
description: Knee joint pain discomfort assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Pain subscore (WOMAC A) ranges from 0 to 100 mm (averaging five VAS 0-100 mm) with higher scores indicating more pain.
measure: Change in WOMAC™ Stiffness
time frame: 12-weeks
description: Knee joint stiffness assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Stiffness subscore (WOMAC B) ranges from 0 to 100 mm (averaging two VAS 0-100 mm) with higher scores indicating more stiffness.
measure: Change in WOMAC™ Physical function
time frame: 12-weeks
description: Knee joint physical function assessed with the validated Western Ontario and McMaster University questionnaire (WOMAC) using its visual analogue scale version (VAS). The WOMAC VA 3.1 Physical function subscore (WOMAC C) ranges from 0 to 100 mm (averaging seventeen VAS 0-100 mm) with higher scores indicating more stiffness.
measure: Change in WOMAC™ Global Index
time frame: 12-weeks
description: Knee joint global discomfort assessed through the sum of WOMAC A (pain), WOMAC B (stiffness) and WOMAC C (physical function) subscores. The WOMAC Global Index score ranges from 0 to 2400 mm (summing up twenty-four VAS 0-100 mm), with higher scores indicating higher disease burden.
measure: Pain intensity at rest
time frame: 12-weeks
description: The pain intensity at rest is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.
measure: Pain intensity while walking
time frame: 12-weeks
description: The pain intensity while walking is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.
measure: "Patient Global Assessment" (PGA)
time frame: 12-weeks
description: The "Patient Global Assessment" (PGA) is the global assessment on joint discomfort and is assessed using a VAS ranging from 0 to 100 mm, with higher scores indicating more pain.
measure: OMERACT-OARSI criteria
time frame: 12-weeks
description: Evaluation of the response to supplementation
measure: 30s Chair Stand Physical Performance
time frame: 12-weeks
description: Evaluation of the maximum number of chair stand repetitions possible in a 30 second period. Scoring results in a wide range of skill levels from 0, for those who cannot complete a single repetition and values greater than 20 for the well prepared individuals.
measure: 40m Fast-paced Walked Physical Performance
time frame: 12-weeks
description: A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) evaluating the ability to walk quickly over short distances. Time of one test trial is recorded and expressed as speed m/s by dividing distance (40m) by time (s).
measure: Stair Climb Physical Performance
time frame: 12-weeks
description: Evaluates the time (in seconds) it takes to ascend and descend a flight of stairs. Timing begins on the signal to start and terminates when the participant returns with both feet to the ground level and the total time to ascend and descend steps for 1 test trial is recorded to nearest 100th of a second.
measure: Time up & Go Physical Performance
time frame: 12-weeks
description: Evaluates the time (seconds) taken to rise from a chair, walk 3 m (9 ft 10 inches), turn, walk back to the chair, then sit down. Timing starts on the signal to start and terminates once the participant sits back down fully with their back resting on the back of the chair. Two trials are performed and the faster of the 2 trials is recorded to nearest 10th of a second.
measure: Quality of Life evaluation
time frame: 12-weeks
description: Evaluation of Quality of life through SF-36 (RAND version), which is a set of generic, coherent, and easily administered quality-of-life measures. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability and the higher the score the less disability.
measure: Clinical Global Impression of Change (CGIC)
time frame: 12-weeks
description: Physician assessment of joint swelling and range of motion (ROM) for knee extension/flexion, indicating the perceived change over the treatment period. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse.
measure: Assessment of use of rescue medicine
time frame: 12-weeks
description: Evaluation of associated treatments needed to manage joint complains
arm group label: TPG
arm group type: Experimental
description: 59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks
arm group label: STE
arm group type: Active Comparator
description: 59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks
arm group label: Control
arm group type: Placebo Comparator
description: 59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks
intervention type: Dietary Supplement
intervention name: Turmipure GOLD®
description: TPG: Turmipure GOLD® capsules - 4 capsules once daily- as prescribed
arm group label: TPG
intervention type: Dietary Supplement
intervention name: Turmeric rhizome PE 95% curcuminoids
description: STE: Turmeric rhizome PE 95% curcuminoids - 4 capsules once daily- as prescribed
arm group label: STE
intervention type: Dietary Supplement
intervention name: Placebo
description: Placebo: Maltodextrin - 4 capsules once daily- as prescribed
arm group label: Control
criteria: 
gender: All
minimum age: 35 Years
maximum age: 80 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Matija Tomšič, Prof., MD
role: Study Chair
affiliation: Univerzitetni klinični center Ljubljana, Klinični oddelek za revmatologijo, Ljubljana, Slovenia
last name: Samo K Fokter, MD
role: Principal Investigator
affiliation: Univerzitetni klinični center Maribor, Oddelek za ortopedijo
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Croatia
country: Slovenia
responsible party type: Sponsor
mesh term: Arthralgia
sharing ipd: Undecided
ipd description: To revisit after investigation period